Not Yet RecruitingNot Applicable

Construction of a Comprehensive Health Management Platform for Patients With Cardiovascular-Kidney-Metabolic Syndrome

150 participantsStarted 2026-03

Plain-language summary

Cardiovascular-Kidney-Metabolic (CKM) syndrome underscores the pathophysiologic interplay among metabolic risk factors, chronic kidney disease (CKD) and the cardiovascular system. This crosstalk precipitates multi-organ dysfunction, increases adverse cardiovascular events, and imposes heavy familial and socioeconomic burdens. Building a health-management platform within research wards is therefore urgent. Such a platform is the pivotal venue for assessment, monitoring, intervention and follow-up in continuous care. Leveraging the existing health-management system of the Health Screening Center at Peking University Third Hospital, the investigators will develop a comprehensive CKM platform that integrates systemic inflammatory biomarkers, cardiovascular early-warning algorithms, and personalized diet-and-exercise prescriptions. The system will provide cyclic management encompassing evaluation, guidance, monitoring, feedback and longitudinal follow-up. A randomized controlled trial with two-year prospective follow-up will enroll patients at CKM stages 0-2 to evaluate clinical improvement, quality of life, dietary behavior and physical activity after platform enrollment. The project will enable early identification of high-risk individuals, deliver precision management, maximize data utility, and offer a novel research-ward model that addresses mobile-health pain points and closes the CKM care loop.

Who can participate

Age range18 Years – 75 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * CKM stage 0-2 as defined by the American Heart Association CKM diagnostic guidelines * Age 18-75 years * Able to use a smartphone and wearable activity tracker * Willing to sign informed consent and attend scheduled follow-up visits Exclusion Criteria: * CKM stage 3-4 * Acute or critically ill conditions requiring hospitalization * Malignant tumors or any active cancer under treatment

What they're measuring

Height

Timeframe: Baseline, Month 12, Month 24

Weight

Timeframe: Baseline, Month 12, Month 24

Systolic Blood Pressure

Timeframe: Baseline, Month 12, Month 24

Diastolic Blood Pressure

Timeframe: Baseline, Month 12, Month 24

Heart Rate on 12-Lead Electrocardiogram

Timeframe: Baseline, Month 12, Month 24

PR Interval on 12-Lead Electrocardiogram

Timeframe: Baseline, Month 12, Month 24

QRS Duration on 12-Lead Electrocardiogram

Timeframe: Baseline, Month 12, Month 24

QTc Interval on 12-Lead Electrocardiogram

Timeframe: Baseline, Month 12, Month 24

Trial details

NCT IDNCT07452029

SponsorPeking University Third Hospital

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2027-12

View on ClinicalTrials.gov More Cardiovascular-Kidney-Metabolic Syndrome trials

Plain-language summary

Who can participate

Age range18 Years – 75 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

What they're measuring

Height

Timeframe: Baseline, Month 12, Month 24

Weight

Timeframe: Baseline, Month 12, Month 24

Systolic Blood Pressure

Timeframe: Baseline, Month 12, Month 24

Diastolic Blood Pressure

Timeframe: Baseline, Month 12, Month 24

Heart Rate on 12-Lead Electrocardiogram

Timeframe: Baseline, Month 12, Month 24

PR Interval on 12-Lead Electrocardiogram

Timeframe: Baseline, Month 12, Month 24

QRS Duration on 12-Lead Electrocardiogram

Timeframe: Baseline, Month 12, Month 24

QTc Interval on 12-Lead Electrocardiogram

Timeframe: Baseline, Month 12, Month 24